Notably, combination therapy with TREM2 knockout and the galectin-3 inhibitor GB1107 substantially inhibited lung cancer progression in vivo by decreasing tumor-infiltrating M2-like macrophages and increasing antitumor CD8+ T and NK cells. Here, TREM2 is linked to lung cancer.